The AHA, joined by the Association of American Medical Colleges and America's Essential Hospitals, today urged a federal appeals court to expedite their appeal of a lower court’s December dismissal of the groups’ lawsuit that sought to prevent Medicare payment cuts for many hospitals in the 340B Drug Pricing Program. Today’s request asked that the United States Court of Appeals for the District of Columbia Circuit establish an expedited schedule that would ensure completion of all briefing in the appeal by no later than the beginning of April and set a date for oral argument as soon as practicable upon completion of the briefing. The request to expedite briefing is joined by the hospitals that were part of the original lawsuit challenging the payment reduction – Eastern Maine Healthcare Systems in Brewer, ME, Henry Ford Health System in Detroit and Adventist Health System's Park Ridge Health in Hendersonville, NC. The lower court on Dec. 29 dismissed the lawsuit as premature, but it did not rule on the merits of the groups’ claim. The groups on Jan. 9 formally notified the court of their appeal.
 

Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…